{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:55:04Z","timestamp":1769637304611,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Huizhi Ascent Project of Xuanwu Hospital","award":["HZ2021ZCLJ005"],"award-info":[{"award-number":["HZ2021ZCLJ005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Identifying DNA mismatch repair deficiency (MMRd) is important for prognosis risk stratification in patients with early-stage endometrial cancer (EC), but there is a notable absence of cost-effective and non-invasive preoperative assessment techniques. The study explored the co-reactivity pattern of glucose metabolism and blood perfusion in EC based on hybrid [<jats:sup>18<\/jats:sup>F]fluorodeoxyglucose ([<jats:sup>18<\/jats:sup>F]FDG) PET\/dynamic contrast enhanced (DCE)-MRI to provide an imaging biomarker for identifying MMRd.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with a history of postmenopausal bleeding and initially diagnosed with EC on ultrasound were recruited to perform a PET\/DCE-MRI scan. Glucose metabolism parameters were calculated on PET, and blood perfusion parameters were calculated semi-automatically by the DCE-Tofts pharmacokinetic model. The MMRd of early-stage EC was evaluated by immunohistochemistry. The synchronous variation of PET and DCE-MRI parameters was compared between the MMRd and mismatch repair proficiency (MMRp). The association between PET\/DCE-MRI and MMRd was analyzed by logistic regression to establish the digital biomarker for predicting MMRd. Receiver operating characteristic curve, decision curve analysis, and the net reclassification index (NRI) were used to evaluate the value of the digital biomarker in identifying MMRd.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eighty-six early-stage EC cases (58.92\u2009\u00b1\u200910.13 years old, 34 MMRd) were enrolled. The max\/mean standardized uptake value (SUV<jats:sub>max<\/jats:sub>\/SUV<jats:sub>mean<\/jats:sub>), metabolic tumor volume, total lesion glycolysis, transfer constant (K<jats:sub>trans<\/jats:sub>), and efflux rate (K<jats:sub>ep<\/jats:sub>) were higher in MMRd than those in MMRp (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001, &lt;\u20090.001, 0.002, 0.004, &lt; 0.001, and 0.005, respectively). The correlations between glucose metabolism and blood perfusion were different between the MMRd and MMRp subgroups. SUV<jats:sub>max<\/jats:sub> was correlated with K<jats:sub>ep<\/jats:sub> (<jats:italic>r<\/jats:italic>\u2009=\u20090.36) in the MMRd. SUV<jats:sub>mean<\/jats:sub> (odds ratio [OR]\u2009=\u20091.32, <jats:italic>P<\/jats:italic>\u2009=\u20090.006) and K<jats:sub>trans<\/jats:sub> (OR\u2009=\u20091.90, <jats:italic>P<\/jats:italic>\u2009=\u20090.021) were independent risk factors for MMRd. And the digital biomarker that combined SUV<jats:sub>mean<\/jats:sub> and K<jats:sub>trans<\/jats:sub> outperformed in identifying MMRd in early-stage EC more than DCE-MRI (AUC: 0.83 vs. 0.78, NRI\u2009=\u200913%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A potential digital biomarker based on [<jats:sup>18<\/jats:sup>F]FDG PET\/DCE-MRI can identify MMRd for prognosis risk stratification in early-stage EC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40644-024-00805-5","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T02:38:44Z","timestamp":1732502324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Co-reactivity pattern of glucose metabolism and blood perfusion revealing DNA mismatch repair deficiency based on PET\/DCE-MRI in endometrial cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Xiaoran","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bixiao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huawei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"805_CR1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/path.5373","volume":"250","author":"A Le\u00f3n-Castillo","year":"2020","unstructured":"Le\u00f3n-Castillo A, Gilvazquez E, Nout R, Smit VT, McAlpine JN, McConechy M, et al. Clinicopathological and molecular characterisation of \u2018multiple\u2010classifier\u2019 endometrial carcinomas. J Pathol. 2020;250:312\u201322.","journal-title":"J Pathol"},{"key":"805_CR2","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","volume":"399","author":"EJ Crosbie","year":"2022","unstructured":"Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399:1412\u201328.","journal-title":"Lancet"},{"key":"805_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ygyno.2016.05.012","volume":"142","author":"D Dai","year":"2016","unstructured":"Dai D, Thiel KW, Salinas EA, Goodheart MJ, Leslie KK, Gonzalez Bosquet J. Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations. Gynecol Oncol. 2016;142:150\u20137.","journal-title":"Gynecol Oncol"},{"key":"805_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","volume":"31","author":"N Concin","year":"2021","unstructured":"Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31:12\u201339.","journal-title":"Int J Gynecol Cancer"},{"key":"805_CR5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ygyno.2023.05.059","volume":"174","author":"E Rios-Doria","year":"2023","unstructured":"Rios-Doria E, Momeni-Boroujeni A, Friedman CF, Selenica P, Zhou Q, Wu M, et al. Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma. Gynecol Oncol. 2023;174:262\u201372.","journal-title":"Gynecol Oncol"},{"key":"805_CR6","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3390\/biomedicines9060632","volume":"9","author":"S Rousset-Rouviere","year":"2021","unstructured":"Rousset-Rouviere S, Rochigneux P, Chr\u00e9tien A-S, Fattori S, Gorvel L, Provansal M, et al. Endometrial carcinoma: Immune Microenvironment and emerging treatments in Immuno-Oncology. Biomedicines. 2021;9:632.","journal-title":"Biomedicines"},{"key":"805_CR7","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/ijgc-2021-002536","volume":"31","author":"G Alban","year":"2021","unstructured":"Alban G, Cheng T, Adleman J, Buzurovic I, Pretz J, Singer L, et al. Definitive radiotherapy for vaginal recurrence of early-stage endometrial cancer: survival outcomes and effect of mismatch repair status. Int J Gynecol Cancer. 2021;31:1007\u201313.","journal-title":"Int J Gynecol Cancer"},{"key":"805_CR8","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1158\/1078-0432.CCR-22-3915","volume":"29","author":"A Oaknin","year":"2023","unstructured":"Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S, et al. Safety, Efficacy, and biomarker analyses of Dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study. Clin Cancer Res. 2023;29:4564\u201374.","journal-title":"Clin Cancer Res"},{"key":"805_CR9","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1136\/ijgc-2022-003492","volume":"32","author":"R Kristeleit","year":"2022","unstructured":"Kristeleit R, Mathews C, Redondo A, Boklage S, Hanlon J, Im E, et al. Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient\/microsatellite instability-high endometrial cancer treated with dostarlimab. Int J Gynecol Cancer. 2022;32:1250\u20137.","journal-title":"Int J Gynecol Cancer"},{"key":"805_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17512433.2022.2044791","volume":"15","author":"A Redondo","year":"2022","unstructured":"Redondo A, Gallego A, Mendiola M. Dostarlimab for the treatment of advanced endometrial cancer. Expert Rev Clin Pharmacol. 2022;15:1\u20139.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"805_CR11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ygyno.2022.06.005","volume":"166","author":"DM O\u2019Malley","year":"2022","unstructured":"O\u2019Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, et al. Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high\/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study. Gynecol Oncol. 2022;166:245\u201353.","journal-title":"Gynecol Oncol"},{"key":"805_CR12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33:929\u201338.","journal-title":"Ann Oncol"},{"key":"805_CR13","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1200\/JCO.21.01874","volume":"40","author":"DM O\u2019Malley","year":"2022","unstructured":"O\u2019Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, et al. Pembrolizumab in patients with microsatellite instability\u2013high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;40:752\u201361.","journal-title":"J Clin Oncol"},{"key":"805_CR14","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2217\/imt-2023-0294","volume":"16","author":"J Xu","year":"2024","unstructured":"Xu J, Mao Y, Xu N, Bai Y, Wang D, Chen X, et al. Pembrolizumab in patients from China with microsatellite instability-high\/mismatch repair deficient tumors: KEYNOTE-158. Immunotherapy. 2024;16:529\u201337.","journal-title":"Immunotherapy"},{"key":"805_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ygyno.2021.10.071","volume":"164","author":"TJ Orellana","year":"2022","unstructured":"Orellana TJ, Kim H, Beriwal S, Bhargava R, Berger J, Buckanovich RJ, et al. Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer. Gynecol Oncol. 2022;164:129\u201335.","journal-title":"Gynecol Oncol"},{"key":"805_CR16","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1200\/JCO.2016.67.8722","volume":"34","author":"DS McMeekin","year":"2016","unstructured":"McMeekin DS, Tritchler DL, Cohn DE, Mutch DG, Lankes HA, Geller MA, et al. Clinicopathologic significance of Mismatch Repair defects in Endometrial Cancer: an NRG Oncology\/Gynecologic Oncology Group Study. J Clin Oncol. 2016;34:3062\u20138.","journal-title":"J Clin Oncol"},{"key":"805_CR17","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/s41379-020-0501-8","volume":"33","author":"A Pasanen","year":"2020","unstructured":"Pasanen A, Loukovaara M, B\u00fctzow R. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma. Mod Pathol. 2020;33:1443\u201352.","journal-title":"Mod Pathol"},{"key":"805_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1007\/s00259-014-2964-7","volume":"42","author":"S Sudo","year":"2015","unstructured":"Sudo S, Hattori N, Manabe O, Kato F, Mimura R, Magota K, et al. FDG PET\/CT diagnostic criteria may need adjustment based on MRI to estimate the presurgical risk of extrapelvic infiltration in patients with uterine endometrial cancer. Eur J Nucl Med Mol Imaging. 2015;42:676\u201384.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"805_CR19","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/MNM.0000000000001654","volume":"44","author":"T Bese","year":"2023","unstructured":"Bese T, Bicer E, Kosuk AT, Akovali B, Turan H, Kabasakal L, et al. The relationship between tumor mean standard uptake value (SUVmax) in preoperative PET\/computed tomography and prognostic risk groups in endometrial cancer. Nucl Med Commun. 2023;44:204\u201311.","journal-title":"Nucl Med Commun"},{"key":"805_CR20","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.21037\/qims-22-688","volume":"13","author":"G Zhang","year":"2023","unstructured":"Zhang G, Yan R, Liu W, Jin X, Wang X, Wang H, et al. Use of biexponential and stretched exponential models of intravoxel incoherent motion and dynamic contrast-enhanced magnetic resonance imaging to assess the proliferation of endometrial carcinoma. Quant Imaging Med Surg. 2023;13:2568\u201381.","journal-title":"Quant Imaging Med Surg"},{"key":"805_CR21","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1007\/s00330-013-2901-3","volume":"23","author":"IS Haldorsen","year":"2013","unstructured":"Haldorsen IS, Gr\u00fcner R, Husby JA, Magnussen IJ, Werner HMJ, Salvesen \u00d8O, et al. Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. Eur Radiol. 2013;23:2916\u201325.","journal-title":"Eur Radiol"},{"key":"805_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40644-022-00452-8","volume":"22","author":"Z Ye","year":"2022","unstructured":"Ye Z, Ning G, Li X, San Koh T, Chen H, Bai W, et al. Endometrial carcinoma: use of tracer kinetic modeling of dynamic contrast-enhanced MRI for preoperative risk assessment. Cancer Imaging. 2022;22:14.","journal-title":"Cancer Imaging"},{"key":"805_CR23","doi-asserted-by":"publisher","first-page":"20210054","DOI":"10.1259\/bjr.20210054","volume":"94","author":"S Satta","year":"2021","unstructured":"Satta S, Dolciami M, Celli V, Di Stadio F, Perniola G, Palaia I, et al. Quantitative diffusion and perfusion MRI in the evaluation of endometrial cancer: validation with histopathological parameters. Br J Radiol. 2021;94:20210054.","journal-title":"Br J Radiol"},{"key":"805_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40644-021-00399-2","volume":"21","author":"B J\u00f3nsd\u00f3ttir","year":"2021","unstructured":"J\u00f3nsd\u00f3ttir B, Ripoll MA, Bergman A, Silins I, Poromaa IS, Ahlstr\u00f6m H, et al. Validation of 18F-FDG PET\/MRI and diffusion-weighted MRI for estimating the extent of peritoneal carcinomatosis in ovarian and endometrial cancer -a pilot study. Cancer Imaging. 2021;21:34.","journal-title":"Cancer Imaging"},{"key":"805_CR25","doi-asserted-by":"crossref","unstructured":"Shih I-L, Yen R-F, Chen C-A, Cheng W-F, Chen B-B, Zheng Q-Y, et al. PET\/MRI in Endometrial Cancer: Imaging Biomarkers are Associated with Disease Progression and Overall Survival. Acad Radiol. 2024;31:939\u201350.","DOI":"10.1016\/j.acra.2023.08.012"},{"key":"805_CR26","doi-asserted-by":"publisher","first-page":"6457","DOI":"10.1158\/1078-0432.CCR-21-1834","volume":"27","author":"AG Rockall","year":"2021","unstructured":"Rockall AG, Barwick TD, Wilson W, Singh N, Bharwani N, Sohaib A, et al. Diagnostic accuracy of FEC-PET\/CT, FDG-PET\/CT, and diffusion-weighted MRI in detection of nodal metastases in surgically treated endometrial and cervical carcinoma. Clin Cancer Res. 2021;27:6457\u201366.","journal-title":"Clin Cancer Res"},{"key":"805_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40336-021-00463-8","volume":"10","author":"C Bezzi","year":"2022","unstructured":"Bezzi C, Zambella E, Ghezzo S, Fallanca F, Gajate AMS, Franchini A, et al. 18F-FDG PET\/MRI in endometrial cancer: systematic review and meta-analysis. Clin Transl Imaging. 2022;10:45\u201358.","journal-title":"Clin Transl Imaging"},{"key":"805_CR28","doi-asserted-by":"publisher","first-page":"E221","DOI":"10.1097\/RLU.0000000000004064","volume":"47","author":"G Ironi","year":"2022","unstructured":"Ironi G, Mapelli P, Bergamini A, Fallanca F, Candotti G, Gnasso C, et al. Hybrid PET\/MRI in staging Endometrial Cancer Diagnostic and Predictive Value in a prospective cohort. Clin Nucl Med. 2022;47:E221-229.","journal-title":"Clin Nucl Med"},{"key":"805_CR29","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/uog.18909","volume":"51","author":"E Epstein","year":"2018","unstructured":"Epstein E, Fischerova D, Valentin L, Testa AC, Franchi D, Sladkevicius P, et al. Ultrasound characteristics of endometrial cancer as defined by International Endometrial Tumor Analysis (IETA) consensus nomenclature: prospective multicenter study. Ultrasound Obstet Gynecol. 2018;51:818\u201328.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"805_CR30","doi-asserted-by":"publisher","first-page":"109190","DOI":"10.1016\/j.ejrad.2020.109190","volume":"130","author":"M Lin","year":"2020","unstructured":"Lin M, Zhang Q, Song Y, Yu X, Ouyang H, Xie L, et al. Differentiation of endometrial adenocarcinoma from adenocarcinoma of cervix using kinetic parameters derived from DCE-MRI. Eur J Radiol. 2020;130:109190.","journal-title":"Eur J Radiol"},{"key":"805_CR31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/annonc\/mdw542","volume":"28","author":"E Stelloo","year":"2017","unstructured":"Stelloo E, Jansen AML, Osse EM, Nout RA, Creutzberg CL, Ruano D, et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol. 2017;28:96\u2013102.","journal-title":"Ann Oncol"},{"key":"805_CR32","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11604-018-0741-4","volume":"36","author":"K Minamiguchi","year":"2018","unstructured":"Minamiguchi K, Takahama J, Uchiyama T, Taiji R, Saito N, Okada H, et al. Uterine endometrial carcinoma with DNA mismatch repair deficiency: magnetic resonance imaging findings and clinical features. Jpn J Radiol. 2018;36:429\u201336.","journal-title":"Jpn J Radiol"},{"key":"805_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13244-021-01126-y","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Liu X, Wang X, Lin C, Qi Y, Chen B, et al. Using amide proton transfer-weighted MRI to non-invasively differentiate mismatch repair deficient and proficient tumors in endometrioid endometrial adenocarcinoma. Insights Imaging. 2021;12:182.","journal-title":"Insights Imaging"},{"key":"805_CR34","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","volume":"22","author":"JC Dudley","year":"2016","unstructured":"Dudley JC, Lin M-T, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22:813\u201320.","journal-title":"Clin Cancer Res"},{"key":"805_CR35","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","volume":"593","author":"B Reinfeld","year":"2021","unstructured":"Reinfeld B, Madden MZ, Wolf MM, Chytil A, Bader JE, Patterson AR, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. 2021;593:282.","journal-title":"Nature"},{"key":"805_CR36","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.21037\/qims-22-189","volume":"12","author":"N Meng","year":"2022","unstructured":"Meng N, Fu F, Sun J, Feng P, Luo Y, Wu Y, et al. Sensitivity and specificity of amide proton transfer-weighted imaging for assessing programmed death-ligand 1 status in non-small cell lung cancer: a comparative study with intravoxel incoherent motion and 18F-FDG PET. Quant Imaging Med Surg. 2022;12:4474\u201387.","journal-title":"Quant Imaging Med Surg"},{"key":"805_CR37","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s12149-023-01869-2","volume":"37","author":"X Sun","year":"2023","unstructured":"Sun X, Yao X, Zeng B, Zhu L, Shang Y, Zhang Q, et al. Association of mismatch repair deficiency in endometrial cancer with 18F-FDG PET\/CT and clinicopathological features and their prognostic value. Ann Nucl Med. 2023;37:655\u201364.","journal-title":"Ann Nucl Med"},{"key":"805_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-93","volume":"10","author":"M Eppenberger","year":"2010","unstructured":"Eppenberger M, Zlobec I, Baumhoer D, Terracciano L, Lugli A. Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer. BMC Cancer. 2010;10: 93.","journal-title":"BMC Cancer"},{"key":"805_CR39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40364-022-00438-5","volume":"10","author":"P \u0141aniewski","year":"2022","unstructured":"\u0141aniewski P, Cui H, Mahnert ND, Mourad J, Borst MP, Willmott L, et al. Protein biomarkers in cervicovaginal lavages for detection of endometrial cancer. Biomark Res. 2022;10:88.","journal-title":"Biomark Res"},{"key":"805_CR40","doi-asserted-by":"publisher","first-page":"0","DOI":"10.4317\/medoral.22210","volume":"23","author":"R Bologna-Molina","year":"2018","unstructured":"Bologna-Molina R, Pereira-Prado V, Sanchez-Romero C, Tapia-Repetto G, Soria S, Hernandez M, et al. Expression of hMLH1 and hMSH2 proteins in ameloblastomas and tooth germs. Med Oral. 2018;23:0\u20130.","journal-title":"Med Oral"},{"key":"805_CR41","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1179\/016164110X12645013515052","volume":"32","author":"AM Stark","year":"2010","unstructured":"Stark AM, Doukas A, Hugo H-H, Mehdorn HM. The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. Neurol Res. 2010;32:816\u201320.","journal-title":"Neurol Res"},{"key":"805_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s12672-022-00466-5","volume":"13","author":"Y Guo","year":"2022","unstructured":"Guo Y, Liu Y, Zhang W, Luo H, Shu P, Chen G, et al. The clinicopathological characteristics, prognosis and immune microenvironment mapping in MSI-H\/MMR-D endometrial carcinomas. Discov Onc. 2022;13:12.","journal-title":"Discov Onc"},{"key":"805_CR43","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","volume":"15","author":"KC Valkenburg","year":"2018","unstructured":"Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15:366\u201381.","journal-title":"Nat Rev Clin Oncol"},{"key":"805_CR44","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/1078-0432.CCR-06-2436","volume":"13","author":"M Jain","year":"2007","unstructured":"Jain M, Venkatraman G, Batra SK. Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin Cancer Res. 2007;13:1374\u201382.","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-024-00805-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-024-00805-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-024-00805-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T19:03:53Z","timestamp":1732561433000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-024-00805-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["805"],"URL":"https:\/\/doi.org\/10.1186\/s40644-024-00805-5","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xuanwu hospital ethics committee (protocol code: Xuanwu hospital [2019]030) approved the study and written patients\u2019 informed consent was obtained in all cases according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}